Editas Medicine (EDIT) Tops Q2 EPS by 6c

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.4 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Worthington Industries (WOR) Misses Q4 EPS by 9c